The capital raise provides Trevi with additional funding for clinical development of Haduvio™, but investors should monitor for share dilution. The stock may react negatively in the near term due to dilution, especially given the lack of revenue or earnings from a still-clinical-stage company.
Price Chart
Executive Summary
Trevi Therapeutics priced an underwritten public offering of 11,600,000 shares at $13.00 per share, raising approximately $150 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 1,740,000 shares. The offering is expected to close on or about April 20, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Trevi Therapeutics is offering 11,600,000 shares of common stock at $13.00 per share.
- Total gross proceeds are approximately $150 million, before underwriting discounts and expenses.
- Underwriters have a 30-day option to purchase up to 1,740,000 additional shares.
- The offering is expected to close around April 20, 2026, subject to customary closing conditions.
- Morgan Stanley, Leerink Partners, Cantor, and Stifel are joint book-running managers.
Financial Impact
$150 million in gross proceeds from issuance of 11.6M shares at $13.00 per share, with potential for additional $22.6 million if the overallotment is exercised.
Risk Factors
- Dilution to existing shareholders upon issuance of new shares.
- Uncertainty around market reception of the offering given current market conditions and the company's pre-revenue status.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275929 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | Institutional Cluster | $13.46 $17.26 | ▲ +28.23% | ▲ +23.84% | $14.12 (+4.90%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.46 $17.26 | ▲ +28.23% | ▲ +23.84% | $14.12 (+4.90%) |
Apr 21, 2026 23w ago | DEFA14A | $14.80 $19.07 | ▲ +28.85% | ▲ +24.07% | $14.12 (−4.59%) |
Apr 20, 2026 23w ago | Press Release | $14.62 $17.36 | ▲ +18.74% | ▲ +11.84% | $14.12 (−3.42%) |
Apr 17, 2026 23w ago | 424B5 | $15.40 $18.15 | ▼ −17.82% | ▼ −11.05% | $14.12 (+8.31%) |
Apr 17, 2026 24w ago | 8-K | $15.23 $17.91 | ▼ −17.60% | ▼ −11.45% | $14.12 (+7.29%) |
Apr 17, 2026 24w ago | Press Release | $15.23 $17.91 | ▲ +17.60% | ▲ +11.45% | $14.12 (−7.29%) |
Mar 17, 2026 28w ago | Press Release | $10.69 $13.46 | ▲ +25.91% | ▲ +14.39% | $14.12 (+32.09%) |
Mar 10, 2026 29w ago | Press Release | $11.94 $13.45 | ▲ +12.65% | ▲ +1.12% | $14.12 (+18.26%) |
Mar 9, 2026 29w ago | Press Release | $11.70 $13.50 | ▲ +15.38% | ▲ +3.40% | $14.12 (+20.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access